Mutational Spectrum of LDLR and PCSK9 Genes Identified in Iranian Patients With Premature Coronary Artery Disease and Familial Hypercholesterolemia

被引:6
|
作者
Moradi, Arman [1 ]
Maleki, Majid [2 ]
Ghaemmaghami, Zahra [2 ]
Khajali, Zahra [2 ]
Noohi, Feridoun [2 ]
Moghadam, Maryam Hosseini [2 ]
Kalyinia, Samira [2 ]
Mowla, Seyed Javad [1 ]
Seidah, Nabil G. [3 ]
Malakootian, Mahshid [2 ]
机构
[1] Tarbiat Modares Univ, Fac Biol Sci, Dept Mol Genet, Tehran, Iran
[2] Iran Univ Med Sci, Cardiogenet Res Ctr, Rajaie Cardiovasc Med & Res Ctr, Tehran, Iran
[3] Univ Montreal, Clin Res Inst Montreal, Biochem Neuroendocrinol Lab, Montreal, PQ, Canada
基金
美国国家科学基金会;
关键词
pre-mature CAD; Familial Hypercholesterolemia; loss-of-function; LDLR; PCSK9 (proprotein convertase subtilisin kexin type 9); RECEPTOR GENE; LIPOPROTEIN; BINDING; CLINICIAN; GUIDANCE; DATABASE; DOMAIN; RISK; FH;
D O I
10.3389/fgene.2021.625959
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Familial hypercholesterolemia (FH) is a common, yet underdiagnosed, genetic disorder characterized by lifelong elevated low-density lipoprotein cholesterol levels, which can increase the risk of early-onset coronary artery disease (CAD). In the present study, we screened the nucleotide variations of the LDLR and PCSK9 genes, as well as a part of the APOB gene, in Iranian patients with FH and premature CAD to find the genetic cause of the disorder. Fifteen unrelated individuals with a clinical diagnosis of FH and premature CAD were recruited. Direct DNA sequencing was applied to screen the whole coding exons and exon-intron boundaries of the LDLR and PCSK9 genes and the main parts of their introns, together with exon 26 of the APOB gene. The pathogenicity of the identified mutations was investigated via either segregation analyses in the family or in silico predictive software. Six different point mutations (p.Cys148Tyr, p.Cys216Tyr, p.Cys302Trp, p.Cys338Trp, p.Leu479Gln, and p.G593Afs*72) in LDLR and a double mutation (p.Asp172His and p.Ala53Val) in both LDLR and PCSK9 genes were identified in seven families with clinically diagnosed FH (43%), whereas no pathogenic mutations were found in eight families with clinically diagnosed FH. This study is the first to identify 1 pathogenic mutation in the LDLR gene (c.1014C > G [p.Cys338Trp]) and to cosegregate it from the affected individual in the family. No mutations were found in the APOB gene, whereas several silent mutations/polymorphisms were identified in the LDLR and PCSK9 genes. Genetic testing and reports on nucleotide alterations in the Iranian population are still limited. Our findings not only further confirm the significant role of FH in the incidence of premature CAD but also enlarge the spectrum of LDLR and PCSK9 variations and exhibit the heterogeneity of FH in Iranians. In patients with no mutation in the examined genes, the disease could be begotten either by a polygenic cause or by gene defects occurring in other related genes and regions not targeted in this study.
引用
收藏
页数:12
相关论文
共 50 条
  • [1] Additive effect of mutations in LDLR and PCSK9 genes on the phenotype of familial hypercholesterolemia
    Pisciotta, Livia
    Oliva, Claudio Priore
    Cefalu, Angelo Baldassare
    Noto, Davide
    Bellocchio, Antonella
    Fresa, Raffaele
    Cantafora, Alfredo
    Patel, Dilip
    Averna, Maurizio
    Tarugi, Patrizia
    Calandra, Sebastiano
    Bertolini, Stefano
    ATHEROSCLEROSIS, 2006, 186 (02) : 433 - 440
  • [2] Effect of mutations in LDLR and PCSK9 genes on phenotypic variability in Tunisian familial hypercholesterolemia patients
    Slimani, Afef
    Jelassi, Awatef
    Jguirim, Imen
    Najah, Mohamed
    Rebhi, Lamia
    Omezzine, Asma
    Maatouk, Faouzi
    Ben Hamda, Khaldoun
    Kacem, Maha
    Rabes, Jean-Pierre
    Abifadel, Marianne
    Boileau, Catherine
    Rouis, Mustapha
    Slimane, Mohamed Naceur
    Varret, Mathilde
    ATHEROSCLEROSIS, 2012, 222 (01) : 158 - 166
  • [3] Functional Analysis of 3′UTR Variants at the LDLR and PCSK9 Genes in Patients with Familial Hypercholesterolemia
    Otero, Javier Sanguino
    Rodriguez-Jimenez, Carmen
    Mostaza Prieto, Jose
    Rodriguez-Antolin, Carlos
    Carazo Alvarez, Ana
    Arrieta Blanco, Francisco
    Rodriguez-Novoa, Sonia
    HUMAN MUTATION, 2024, 2024
  • [4] The LDLR, APOB, and PCSK9 Variants of Index Patients with Familial Hypercholesterolemia in Russia
    Meshkov, Alexey
    Ershova, Alexandra
    Kiseleva, Anna
    Zotova, Evgenia
    Sotnikova, Evgeniia
    Petukhova, Anna
    Zharikova, Anastasia
    Malyshev, Pavel
    Rozhkova, Tatyana
    Blokhina, Anastasia
    Limonova, Alena
    Ramensky, Vasily
    Divashuk, Mikhail
    Khasanova, Zukhra
    Bukaeva, Anna
    Kurilova, Olga
    Skirko, Olga
    Pokrovskaya, Maria
    Mikova, Valeriya
    Snigir, Ekaterina
    Akinshina, Alexsandra
    Mitrofanov, Sergey
    Kashtanova, Daria
    Makarov, Valentin
    Kukharchuk, Valeriy
    Boytsov, Sergey
    Yudin, Sergey
    Drapkina, Oxana
    GENES, 2021, 12 (01) : 1 - 17
  • [5] CHARACTERIZATION OF THE EFFECTS OF FAMILIAL HYPERCHOLESTEROLEMIA MUTATIONS IN LDLR ON PCSK9 BINDING
    Deng, Shijun
    Alabi, Adekunle
    Zhang, Dawei
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 55 - 55
  • [6] Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India
    Reddy, Lakshmi Lavanya
    Shah, Swarup A. V.
    Ponde, Chandrashekhar K.
    Dalal, Jamshed J.
    Jatale, Raj G.
    Dalal, Reeta J.
    Rajani, Rajesh M.
    Pillai, Sudhir K.
    Vanjani, Chander V.
    Ashavaid, Tester F.
    JOURNAL OF HUMAN GENETICS, 2021, 66 (10) : 983 - 993
  • [7] Impact of LDLR and PCSK9 pathogenic variants in Japanese heterozygous familial hypercholesterolemia patients
    Hori, Mika
    Ohta, Naotaka
    Takahashi, Atsushi
    Masuda, Hiroaki
    Isoda, Rieko
    Yamamoto, Suguru
    Son, Cheol
    Ogura, Masatsune
    Hosoda, Kiminori
    Miyamoto, Yoshihiro
    Harada-Shiba, Mariko
    ATHEROSCLEROSIS, 2019, 289 : 101 - 108
  • [8] Screening of PCSK9 and LDLR genetic variants in Familial Hypercholesterolemia (FH) patients in India
    Lakshmi Lavanya Reddy
    Swarup A. V. Shah
    Chandrashekhar K. Ponde
    Jamshed J. Dalal
    Raj G. Jatale
    Reeta J. Dalal
    Rajesh M. Rajani
    Sudhir K. Pillai
    Chander V. Vanjani
    Tester F. Ashavaid
    Journal of Human Genetics, 2021, 66 : 983 - 993
  • [9] The Molecular Basis of Familial Hypercholesterolemia in Lebanon: Spectrum of LDLR Mutations and Role of PCSK9 as a Modifier Gene
    Abifadel, Marianne
    Rabes, Jean-Pierre
    Jambart, Selim
    Halaby, Georges
    Gannage-Yared, Marie-Helene
    Sarkis, Antoine
    Beaino, Ghada
    Varret, Mathilde
    Salem, Nabiha
    Corbani, Sandra
    Aydenian, Hermine
    Junien, Claudine
    Munnich, Arnold
    Boileau, Catherine
    HUMAN MUTATION, 2009, 30 (07) : E682 - E691
  • [10] PCSK9 inhibitor use during pregnancy in a case of familial hypercholesterolemia complicated with coronary artery disease
    Suzuki, Takuma
    Tsurane, Kotoi
    Umemoto, Tomoyuki
    Sasano, Tetsuo
    Ushiki, Eiko
    Fudono, Ayako
    Hirose, Asuka
    Sekiguchi, Masaki
    Miyasaka, Naoyuki
    JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH, 2024, 50 (01) : 128 - 132